A new study shows that a biomedical tool can successfully deliver genetic material to edit faulty genes in developing fetal ...
Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...
A new vaccine provides hope for treating and even preventing the highly contagious and difficult-to-treat Clostridioides ...
On Thursday, Moderna Inc (MRNA) stock saw a decline, ending the day at $52.8 which represents a decrease of $-0.59 or -1.11% from the prior close of $53.39. The stock opened at $53.39 and touched a ...
The discovery of the first mRNA-stabilizing substance could pave the way for groundbreaking advancements in the development ...
With exclusive FDA insight, the 4th mRNA Analytical Development & Quality Control Summit returns; uniting the Analytical, ...
We recently published a list of 10 Best Depressed Stocks To Buy Heading into 2025. In this article, we are going to take a ...
Pharmaceutical Technology on MSN3d
A slow start for self-amplifying mRNA vaccines
A year after the first samRNA vaccine approval, experts say others are likely to face scientific and regulatory hurdles.
Scientists in Australia have found why mRNA vaccines trigger side effects, paving the way for more effective vaccines.
Moderna shares rebound after six days of losses. Analysts mixed on stock with Strong Sell rating but potential for future growth.
Prenatal gene therapy via mRNA LNPs fixes faulty genes in fetal brain cells in animal model of neurodevelopmental syndrome.
A single COVID-19 mRNA vaccine dose provided similar protection to that conferred by a 2-dose series among immunocompetent patients aged 5 years and older.